STOCK TITAN

Certara Reports Third Quarter 2024 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags

Certara (NASDAQ: CERT) reported Q3 2024 financial results with revenue of $94.8 million, up 11% year-over-year. Software revenue grew 15% to $35.9 million, while services revenue increased 9% to $58.9 million. The company posted a net loss of $1.4 million, significantly improved from a $49.0 million loss in Q3 2023. Adjusted EBITDA rose 15% to $33.1 million. Total bookings grew 13% to $96.1 million. The company updated its full-year 2024 guidance, expecting revenue between $380-385 million and adjusted EBITDA of $120-124 million.

Certara (NASDAQ: CERT) ha riportato i risultati finanziari per il terzo trimestre del 2024, con un fatturato di $94,8 milioni, in aumento dell'11% rispetto all'anno precedente. I ricavi software sono cresciuti del 15% a $35,9 milioni, mentre i ricavi da servizi sono aumentati del 9% a $58,9 milioni. L'azienda ha registrato una perdita netta di $1,4 milioni, notevolmente migliorata rispetto a una perdita di $49,0 milioni nel Q3 2023. L'EBITDA rettificato è aumentato del 15% a $33,1 milioni. Gli ordini totali sono cresciuti del 13% a $96,1 milioni. L'azienda ha aggiornato le previsioni per l'intero anno 2024, prevedendo un fatturato compreso tra $380-385 milioni e un EBITDA rettificato di $120-124 milioni.

Certara (NASDAQ: CERT) reportó resultados financieros del tercer trimestre de 2024 con ingresos de $94,8 millones, un aumento del 11% interanual. Los ingresos por software crecieron un 15% hasta $35,9 millones, mientras que los ingresos por servicios aumentaron un 9% hasta $58,9 millones. La compañía registró una pérdida neta de $1,4 millones, una mejora significativa con respecto a una pérdida de $49,0 millones en el Q3 2023. El EBITDA ajustado aumentó un 15% hasta $33,1 millones. Las reservas totales crecieron un 13% hasta $96,1 millones. La compañía actualizó su guía para todo el año 2024, esperando ingresos entre $380-385 millones y un EBITDA ajustado de $120-124 millones.

Certara (NASDAQ: CERT)는 2024년 3분기 재무 결과를 보고했으며, 매출은 $94.8 백만으로 전년 대비 11% 증가했습니다. 소프트웨어 매출은 15% 증가하여 $35.9 백만에 도달했으며, 서비스 매출은 9% 증가하여 $58.9 백만에 이르렀습니다. 회사는 $1.4 백만의 순손실을 기록하였으며, 이는 2023년 3분기 $49.0 백만 손실에 비해 상당히 개선된 수치입니다. 조정된 EBITDA는 15% 증가하여 $33.1 백만에 달했습니다. 총 예약 판매는 13% 증가하여 $96.1 백만에 도달했습니다. 회사는 2024년 전체 연도 가이드를 업데이트하여 매출이 $380-385 백만, 조정된 EBITDA가 $120-124 백만에 이를 것으로 예상하고 있습니다.

Certara (NASDAQ: CERT) a publié les résultats financiers pour le troisième trimestre 2024, avec un chiffre d'affaires de $94,8 millions, en hausse de 11% par rapport à l'année précédente. Les revenus logiciels ont augmenté de 15% pour atteindre $35,9 millions, tandis que les revenus de services ont augmenté de 9% pour atteindre $58,9 millions. L'entreprise a enregistré une perte nette de $1,4 millions, ce qui représente une amélioration significative par rapport à une perte de $49,0 millions au T3 2023. L'EBITDA ajusté a augmenté de 15% pour atteindre $33,1 millions. Le total des réservations a augmenté de 13% pour atteindre $96,1 millions. L'entreprise a mis à jour ses prévisions pour l'année entière 2024, s'attendant à un chiffre d'affaires compris entre $380-385 millions et un EBITDA ajusté de $120-124 millions.

Certara (NASDAQ: CERT) hat die finanziellen Ergebnisse für das 3. Quartal 2024 veröffentlicht, mit Einnahmen von $94,8 Millionen, was einem Anstieg von 11% im Jahresvergleich entspricht. Der Softwareumsatz stieg um 15% auf $35,9 Millionen, während der Umsatz aus Dienstleistungen um 9% auf $58,9 Millionen zunahm. Das Unternehmen verzeichnete einen Nettoverlust von $1,4 Millionen, was eine erhebliche Verbesserung gegenüber einem Verlust von $49,0 Millionen im 3. Quartal 2023 darstellt. Das bereinigte EBITDA stieg um 15% auf $33,1 Millionen. Die Gesamtbuchungen stiegen um 13% auf $96,1 Millionen. Das Unternehmen aktualisierte seine Prognose für das Gesamtjahr 2024 und erwartet einen Umsatz zwischen $380-385 Millionen und ein bereinigtes EBITDA von $120-124 Millionen.

Positive
  • Revenue growth of 11% YoY to $94.8 million
  • Software revenue increased 15% to $35.9 million
  • Adjusted EBITDA grew 15% to $33.1 million
  • Total bookings up 13% to $96.1 million
  • Net loss significantly reduced from $49.0M to $1.4M
Negative
  • Services growth impacted by cautious spending among large biopharma customers
  • Weaker performance in regulatory services business
  • Still operating at a net loss of $1.4 million

Insights

The Q3 2024 results show mixed performance with some positive indicators despite challenges. Revenue grew 11% to $94.8 million, with software revenue showing strong growth of 15% at $35.9 million. The significant reduction in net loss from $49.0 million to $1.4 million is notable, though primarily due to the absence of last year's goodwill impairment.

The company's core biosimulation software business remains robust, but services face headwinds from cautious spending by large biopharma customers. The updated guidance range of $380-385 million for full-year revenue suggests some conservatism in Q4 expectations. Healthy bookings growth of 13% and improved adjusted EBITDA margins indicate operational efficiency, but the revised outlook warrants attention to execution in the coming quarters.

Updates Full Year 2024 Financial Guidance

RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024.

Third Quarter Highlights:

  • Revenue was $94.8 million, compared to $85.6 million in the third quarter of 2023, representing growth of 11%.
    • Software revenue was $35.9 million, compared to $31.3 million in the third quarter of 2023, representing growth of 15%.
    • Services revenue was $58.9 million, compared to $54.2 million in the third quarter of 2023, representing growth of 9%.
  • Net loss was $1.4 million, compared to a net loss of $49.0 million in the third quarter of 2023.
    • The $47.6 million increase was primarily due to a $47.0 million decrease in goodwill impairment expense.
  • Adjusted EBITDA was $33.1 million, compared to $28.8 million in the third quarter of 2023, representing growth of 15%.

"Certara’s results demonstrated strength in biosimulation software and services which are the result of our continued investment in biosimulation," said William F. Feehery, Chief Executive Officer. “Following the close of the Chemaxon transaction, we are focused on integrating our software capabilities to generate a best-in-class, lab-to-clinic biosimulation platform."

"We are pleased with the growth in our software business. Our services business was mixed, with biosimulation services growing 13% offset by weaker performance in our regulatory services business. In the second half of the year, we will continue to diligently manage our expense structure to support demand for core biosimulation software and services," said John Gallagher, Chief Financial Officer.

Third Quarter 2024 Results

Total revenue for the third quarter of 2024 was $94.8 million, representing year-over-year growth of 11% on a reported basis and 10% on a constant currency basis. The overall increase in revenue was primarily due to growth in our biosimulation software portfolio. Please see note (1) in the section A Note on Non-GAAP Financial Measures below for more information on constant currency revenue.

Software revenue for the third quarter of 2024 was $35.9 million, representing year-over-year growth of 15% on a reported basis and 14% on a constant currency basis. Software growth was driven by biosimulation software and Pinnacle 21.

Services revenue for the third quarter of 2024 was $58.9 million, representing year-over-year growth of 9% on a reported basis and 8% on a constant currency basis. Services growth was impacted by cautious spending among large biopharma customers.

Total Bookings for the third quarter of 2024 were $96.1 million representing a year-over-year growth of 13% on a reported basis.

Software Bookings for the third quarter of 2024 were $34.8 million, representing a year-over-year growth of 28%. The increase in software bookings was primarily due to strength in Certara’s core biosimulation software and Pinnacle 21.

Services Bookings for the third quarter of 2024 were $61.3 million, representing a year-over-year growth of 6% on a reported basis.

Total cost of revenue for the third quarter of 2024 was $37.2 million, an increase of $1.3 million from $35.9 million in the third quarter of 2023, primarily due to increases in employee-related expenses and software amortization.

Total operating expenses for the third quarter of 2024 were $55.0 million, which decreased by $47.4 million from $102.5 million in the third quarter of 2023. Lower operating expenses were primarily due to a $47.0 million decrease in goodwill impairment expense, as well as a strategic re-allocation of resources made during the second quarter of 2024 to optimize Certara’s cost structure.

Adjusted EBITDA for the third quarter of 2024 was $33.1 million compared to $28.8 million for the third quarter of 2023, an increase of $4.2 million. See note (2) in the section A Note on Non-GAAP Financial Measures below for more information on adjusted EBITDA.

Diluted loss per share for the third quarter 2024 was $0.01, as compared to a diluted loss per share of $0.31 in the third quarter of 2023.

Net loss for the third quarter of 2024 was $1.4 million, compared to a net loss of $49.0 million in the third quarter of 2023. The $47.6 million increase was primarily due to lower operating expenses.

Adjusted net income for the third quarter of 2024 was $20.3 million compared to $17.1 million for the third quarter of 2023, an increase of $3.2 million. Adjusted diluted earnings per share for the third quarter 2024 was $0.13 compared to $0.11 for the third quarter of 2023. See note (3) in the section A Note on Non-GAAP Financial Measures below for more information on adjusted net income and adjusted diluted earnings per share.

  THREE MONTHS ENDED
SEPTEMBER 30,
NINE MONTHS ENDED
SEPTEMBER 30,
   2024   2023  2024   2023 
Key Financials (in millions, except per share data)
Revenue $94.8  $85.6 $284.8  $266.3 
Software revenue $35.9  $31.3 $113.4  $98.1 
Service revenue $58.9  $54.2 $171.4  $168.3 
Total bookings $96.1  $84.8 $300.8  $283.4 
Software bookings $34.8  $27.2 $109.8  $93.6 
Service bookings $61.3  $57.6 $191.0  $189.8 
Net income (loss) $(1.4) $(49.0)$(18.6) $(42.9)
Diluted earnings per share $(0.01) $(0.31)$(0.12) $(0.27)
Adjusted EBITDA $33.1  $28.8 $88.5  $93.5 
Adjusted net income $20.3  $17.1 $48.2  $54.7 
Adjusted diluted earnings per share $0.13  $0.11 $0.30  $0.34 
Cash and cash equivalents    $233.0  $272.3 
            

2024 Financial Outlook

Certara is updating its 2024 outlook, and expects the following:

  • Full year 2024 revenue to be in the range of $380 million to $385 million.
  • Full year adjusted EBITDA to be in the range of $120 million to $124 million.
  • Full year adjusted diluted earnings per share is expected to be in the range of $0.41 - $0.44.
  • Fully diluted shares are expected to be in the range of 160 million to 162 million.

Webcast and Conference Call Details

Certara will host a conference call today, November 6, 2024, at 5:00 p.m. ET to discuss its third quarter 2024 financial results. Investors interested in listening to the conference call are required to register online in advance of the call. A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com.

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include nearly 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries.

Please visit our website at www.certara.com. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.

Such disclosures will be included in the Investor Relations section of our website at https://ir.certara.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, Securities and Exchange Commission filings and public conference calls and webcasts.

Forward-Looking Statements

This press release contains certain statements that constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, with respect to the Company’s full-year guidance and other statements about the Company’s future business and financial performance, revenue, margin, and bookings. These statements typically contain words such as “believe,” “may,” “potential,” “will,” “plan,” “could,” “estimate,” “expects” and “anticipates” or the negative of these words or other similar terms or expressions. Any statement in this press release that is not a statement of historical fact is a forward-looking statement and involves significant risks and uncertainties. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot provide any assurance that these expectations will prove to be correct. You should not rely upon forward-looking statements as predictions of future events and actual results, events, or circumstances. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the Company’s ability to compete within its market; any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery; changes or delays in relevant government regulation; increasing competition, regulation and other cost pressures within the pharmaceutical and biotechnology industries; economic conditions, including inflation, recession, currency exchange fluctuation and adverse developments in the financial services industry; trends in research and development (R&D) spending; delays or cancellations in projects due to supply chain interruptions or disruptions or delays to pipeline development and clinical trials experienced by our customers; consolidation within the biopharmaceutical industry; reduction in the use of the Company’s products by academic institutions; pricing pressures; the Company’s ability to successfully enter new markets, increase its customer base and expand its relationships with existing customers; the impact of acquisitions and our ability to successfully integrate such acquisitions; the occurrence of natural disasters and epidemic diseases; any delays or defects in the release of new or enhanced software or other biosimulation tools; failure of our existing customers to renew their software licenses or any delays or terminations of contracts or reductions in scope of work by its existing customers; our ability to accurately estimate costs associated with its fixed-fee contracts; our ability to retain key personnel or recruit additional qualified personnel; risks related to the mischaracterization of our independent contractors; lower utilization rates by our employees as a result of natural disasters and epidemic diseases; risks related to our contracts with government customers; our ability to sustain recent growth rates; our ability to successfully operate a global business; our ability to comply with applicable laws and regulations; risks related to litigation; the adequacy of its insurance coverage and ability to obtain adequate insurance coverage in the future; our ability to perform in accordance with contractual requirements, regulatory standards and ethical considerations; the loss of more than one of our major customers; future capital needs; the ability of our bookings to accurately predict future revenue and our ability to realize revenue on bookings; disruptions in the operations of the third-party providers who host our software solutions or any limitations on their capacity; our ability to reliably meet data storage and management requirements, or the experience of any failures or interruptions in the delivery of our services over the internet; our ability to comply with the terms of any licenses governing use of third-party open source software; any breach of its security measures or unauthorized access to customer data; risks relating to the use of artificial intelligence and machine learning in our products and services; our ability to adequately enforce or defend ownership and use of our intellectual property and other proprietary rights; any allegations of infringement, misappropriation or violations of a third party’s intellectual property rights; our ability to meet obligations under indebtedness and have sufficient capital to operate our business; any limitations on our ability to pursue business strategies due to restrictions under our current or future indebtedness; any additional impairment of goodwill or other intangible assets; our ability to use our net operating losses and R&D tax credit carryforwards; the accuracy of management’s estimates and judgments relating to critical accounting policies and changes in financial reporting standards or interpretations; any inability to design, implement, and maintain effective internal controls or inability to remediate any internal controls deemed ineffective; the costs and management time associated with operating as a publicly traded company; and the other factors detailed under the captions “Risk Factors” and “Special Note Regarding Forward-Looking Statements” and elsewhere in our Securities and Exchange Commission (“SEC”) filings, and reports, including the Form 10-K filed by the Company with the Securities and Exchange Commission on February 29, 2024, and subsequent reports filed with the SEC. Any forward-looking statements speak only as of the date of this release and, except to the extent required by applicable securities laws, we expressly disclaim any obligation to update or revise any of them to reflect actual results, any changes in expectations or any change in events.

A Note on Non-GAAP Financial Measures

This press release contains “non-GAAP measures” which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Specifically, the Company makes use of the non-GAAP financial measures adjusted EBITDA, adjusted net income (loss), adjusted diluted earnings per share, and constant currency (“CC”) revenue, which are not recognized terms under GAAP. These measures should not be considered as alternatives to net income (loss) or GAAP diluted earnings per share or revenue as measures of financial performance or any other performance measure derived in accordance with GAAP and should not be considered a measure of discretionary cash available to the Company to invest in the growth of its business. The presentation of these measures has limitations as an analytical tool and should not be considered in isolation, or as a substitute for the Company’s results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

You should refer to the footnotes below as well as the “Non-GAAP Financial Measures” section in this press release below for a further explanation of these measures and reconciliations of these non-GAAP measures in specific periods to their most directly comparable financial measure calculated and presented in accordance with GAAP for those periods.

Management uses various financial metrics, including total revenues, income (loss) from operations, net income (loss), and certain non-GAAP measures, including those discussed above, to measure and assess the performance of the Company’s business, to evaluate the effectiveness of its business strategies, to make budgeting decisions, to make certain compensation decisions, and to compare the Company’s performance against that of other peer companies using similar measures. In addition, management believes these metrics provide useful measures for period-to-period comparisons of the Company’s business, as they remove the effect of certain non-cash expenses and other items not indicative of its ongoing operating performance.

Management believes that adjusted EBITDA, adjusted net income (loss), adjusted diluted earnings per share, and CC revenue are helpful to investors, analysts, and other interested parties because they can assist in providing a more consistent and comparable overview of our operations across our historical periods. In addition, each of these measures is frequently used by analysts, investors, and other interested parties to evaluate and assess performance. Furthermore, our business has operations outside the United States that are conducted in local currencies. As a result, the comparability of the financial results reported in U.S. dollars is affected by changes in foreign currency exchange rates. We adjust revenues for constant currency to provide a framework for assessing how our business performed excluding the effect of foreign currency rate fluctuations and we believe it is helpful for investors to present operating results on a comparable basis period over period to evaluate its underlying performance.

Please note that the Company has not reconciled the adjusted EBITDA or adjusted diluted earnings per share forward-looking guidance included in this press release to the most directly comparable GAAP measures because this cannot be done without unreasonable effort due to the variability and low visibility with respect to costs related to acquisitions, financings, and employee stock compensation programs, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.

(1)CC revenue excludes the effects of foreign currency exchange rate fluctuations by assuming constant foreign currency exchange rates used for translation. Current periods revenue reported in currencies other than U.S. Dollars are converted into U.S. Dollars at the average exchange rates in effect for the comparable prior periods.
  
(2)Adjusted EBITDA represents net income excluding interest expense, provision (benefit) for income taxes, depreciation and amortization expense, intangible asset amortization, equity-based compensation expense, goodwill impairment, change in fair value of contingent consideration, acquisition and integration expense and other items not indicative of our ongoing operating performance.
  
(3)Adjusted net income and adjusted diluted earnings per share exclude the effect of equity-based compensation expense, amortization of acquisition-related intangible assets, goodwill impairment, change in fair value of contingent consideration, acquisition and integration expense, and other items not indicative of our ongoing operating performance as well as income tax provision adjustment for such charges.
  

In evaluating adjusted EBITDA, adjusted net income, and adjusted diluted earnings per share, you should be aware that in the future the Company may incur expenses similar to those eliminated in this presentation and this presentation should not be construed as an inference that future results will be unaffected by unusual items.

Contacts:

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:
Alyssa Horowitz
Pan Communications
certara@pancomm.com

 
CERTARA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
 
(IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA)

 THREE MONTHS ENDED
SEPTEMBER 30,
 NINE MONTHS ENDED
SEPTEMBER 30,
  2024   2023   2024   2023 
Total revenue $94,820  $85,576  $284,787  $266,327 
Cost of revenues  37,189   35,876   116,253   106,956 
Operating expenses:        
Sales and marketing  11,347   7,238   34,247   23,351 
Research and development  8,271   8,980   29,333   26,155 
General and administrative  22,030   27,760   73,080   61,777 
Intangible asset amortization  12,950   11,155   38,286   32,272 
Depreciation and amortization expense  439   367   1,322   1,139 
Goodwill impairment expense     46,984      46,984 
Total operating expenses  55,037   102,484   176,268   191,678 
Income (loss) from operations  2,594   (52,784)  (7,734)  (32,307)
Other income (expenses):        
Interest expense  (5,187)  (5,903)  (16,516)  (17,046)
Net other income  932   5,078   4,886   6,594 
Total other expenses  (4,255)  (825)  (11,630)  (10,452)
Loss before income taxes  (1,661)  (53,609)  (19,364)  (42,759)
Provision (benefit) for income taxes  (290)  (4,644)  (736)  142 
Net loss $(1,371) $(48,965) $(18,628) $(42,901)
         
Net income (loss) per share attributable to common stockholders:      
Basic $(0.01) $(0.31) $(0.12) $(0.27)
Diluted $(0.01) $(0.31) $(0.12) $(0.27)
Weighted average common shares outstanding:        
Basic  160,642,052   159,165,206   160,225,375   158,769,638 
Diluted  160,642,052   159,165,206   160,225,375   158,769,638 


 
CERTARA, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(UNAUDITED) 
     
(IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA) SEPTEMBER 30,
2024
 DECEMBER 31,
2023
Assets    
Current assets:    
Cash and cash equivalents $233,023  $234,951 
Accounts receivable, net of allowances for credit losses of $1,556 and $1,312  95,956   84,857 
Prepaid expenses and other current assets  21,630   20,393 
Total current assets  350,609   340,201 
Other assets:    
Property and equipment, net  2,554   2,670 
Operating lease right-of-use assets  12,070   9,604 
Goodwill  718,483   716,333 
Intangible assets, net of $323,609 and $273,522 respectively  453,225   487,043 
Deferred income taxes  4,236   4,236 
Other long-term assets  2,052   3,053 
Total assets $1,543,229  $1,563,140 
Liabilities and stockholders' equity    
Current liabilities:    
Accounts payable $2,494  $5,171 
Accrued expenses  53,294   56,779 
Current portion of deferred revenue  59,336   60,678 
Current portion of long-term debt  3,000   3,020 
Other current liabilities  4,581   4,375 
Total current liabilities  122,705   130,023 
Long-term liabilities:    
Deferred revenue, net of current portion  1,177   1,070 
Deferred income taxes  37,554   50,826 
Operating lease liabilities, net of current portion  10,420   6,955 
Long-term debt, net of current portion and debt discount  293,053   288,217 
Other long-term liabilities  24,915   39,209 
Total liabilities  489,824   516,300 
Commitments and contingencies    
Stockholders' equity    
Preferred shares, $0.01 par value, 50,000,000 shares authorized, no shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively      
Common shares, $0.01 par value, 600,000,000 shares authorized, 161,791,989 and 160,284,901 shares issued,160,900,211 and 159,848,286 shares outstanding as of September 30,2024 and December 31, 2023, respectively  1,618   1,603 
Additional paid-in capital  1,209,196   1,178,461 
Accumulated deficit  (134,858)  (116,230)
Accumulated other comprehensive loss  (5,013)  (7,593)
Treasury stock at cost, 891,778 and 436,615 shares at September 30, 2024 and December 31, 2023, respectively  (17,538)  (9,401)
Total stockholders' equity  1,053,405   1,046,840 
Total liabilities and stockholders' equity $1,543,229  $1,563,140 


 
CERTARA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED) 
 
  NINE MONTHS ENDED
SEPTEMBER 30,
(IN THOUSANDS)  2024   2023 
Cash flows from operating activities:    
Net loss $(18,628) $(42,901)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization of property and equipment  1,322   1,139 
Amortization of intangible assets  48,495   40,099 
Amortization of debt issuance costs  891   1,146 
(Recovery of) provision for credit losses  393   52 
Equity-based compensation expense  27,043   20,798 
Change in fair value of contingent considerations  8,092   11,316 
Goodwill impairment     46,984 
Deferred income taxes  (12,626)  (18,532)
Changes in assets and liabilities:    
Accounts receivable  (10,973)  6,441 
Prepaid expenses and other assets  (2,473)  85 
Accounts payable, accrued expenses, and other liabilities  (9,774)  (1,851)
Deferred revenues  (2,122)  (6,978)
Other operating activities, net  1,457   1,631 
Net cash provided by operating activities  31,097   59,429 
Cash flows from investing activities:    
Capital expenditures  (1,210)  (899)
Capitalized software development costs  (13,995)  (10,000)
Investment in intangible assets     (54)
Business acquisitions, net of cash acquired     (7,550)
Net cash used in investing activities  (15,205)  (18,503)
Cash flows from financing activities:    
Proceeds from borrowings on term loan debt  6,305    
Payment of debt issuance costs  (1,216)   
Payments on long-term debt and finance lease obligations  (1,505)  (2,290)
Payments for business acquisition related contingent consideration  (15,156)   
Payment of taxes on shares withheld for employee taxes  (8,135)  (5,905)
Net cash used in financing activities  (19,707)  (8,195)
Effect of foreign exchange rate on cash and cash equivalents, and restricted cash  1,887   (107)
Net increase (decrease) in cash and cash equivalents, and restricted cash  (1,928)  32,624 
Cash and cash equivalents, and restricted cash, at beginning of period  234,951   239,688 
Cash and cash equivalents, and restricted cash, at end of period $233,023  $272,312 

 

 
NON-GAAP FINANCIAL MEASURES
 
The following table reconciles net loss to adjusted EBITDA:
 
  THREE MONTHS ENDED
SEPTEMBER 30,
NINE MONTHS ENDED
SEPTEMBER 30,
   2024   2023  2024   2023 
  (in thousands)
Net loss(a) $(1,371) $(48,965)$(18,628) $(42,901)
Interest expense(a)  5,187   5,903  16,516   17,046 
Interest income(a)  (2,609)  (2,864) (7,669)  (6,428)
(Benefit from) Provision for income taxes(a)  (290)  (4,644) (736)  142 
Depreciation and amortization expense(a)  439   367  1,322   1,139 
Intangible asset amortization(a)  16,353   13,813  48,495   40,099 
Currency (gain) loss(a)  1,546   (2,179) 2,526   (165)
Equity-based compensation expense(b)  8,187   8,645  27,043   20,798 
Change in fair value of contingent consideration(d)  2,431   8,757  8,092   11,316 
Goodwill impairment expense(e)     46,984     46,984 
Acquisition-related expenses(f)  1,364   1,392  4,151   3,276 
Integration expense(g)     33     190 
Transaction - related expenses (h)  (128)    2,625    
Severance expense(i)       183    
Reorganization expense(j)  1,730   1,602  3,944   1,602 
Loss on disposal of fixed assets(k)       13   29 
Executive recruiting expense(l)  222     645   396 
Adjusted EBITDA $33,061  $28,844 $88,522  $93,523 
                

The following table reconciles net loss to adjusted net income:

        
  THREE MONTHS ENDED
SEPTEMBER 30,
NINE MONTHS ENDED
SEPTEMBER 30,
   2024   2023  2024   2023 
  (in thousands)
Net loss (a) $(1,371) $(48,965)$(18,628) $(42,901)
Currency (gain) loss(a)  1,546   (2,179) 2,526   (165)
Equity-based compensation expense(b)  8,187   8,645  27,043   20,798 
Amortization of acquisition-related intangible assets(c)  13,351   11,377  40,041   33,892 
Change in fair value of contingent consideration(d)  2,431   8,757  8,092   11,316 
Goodwill impairment expense(e)     46,984     46,984 
Acquisition-related expenses(f)  1,364   1,392  4,151   3,276 
Integration expense(g)     33     190 
Transaction - related expenses (h)  (128)    2,625    
Severance expense(i)       183    
Reorganization expense(j)  1,730   1,602  3,944   1,602 
Loss on disposal of fixed assets(k)       13   29 
Executive recruiting expense(l)  222     645   396 
Income tax expense impact of adjustments(m)  (7,079)  (10,572) (22,442)  (20,669)
Adjusted net income $20,253  $17,074 $48,193  $54,748 
                

The following tables reconciles diluted earnings per share to adjusted diluted earnings per share:

        
  THREE MONTHS ENDED
SEPTEMBER 30,
NINE MONTHS ENDED
SEPTEMBER 30,
   2024   2023  2024   2023 
  (In thousands except share and per share data)
Diluted earnings per share(a) $(0.01) $(0.31)$(0.12) $(0.27)
Currency (gain) loss(a)  0.01   (0.01) 0.02    
Equity-based compensation expense(b)  0.05   0.06  0.17   0.13 
Amortization of acquisition-related intangible assets(c)  0.08   0.07  0.25   0.21 
Change in fair value of contingent consideration(d)  0.02   0.05  0.05   0.07 
Goodwill impairment expense(e)     0.30     0.30 
Acquisition-related expenses(f)  0.01   0.01  0.03   0.02 
Integration expense(g)           
Transaction - related expenses (h)       0.02    
Severance expense(i)           
Reorganization expense(j)  0.01   0.01  0.02   0.01 
Loss on disposal of fixed assets(k)           
Executive recruiting expense(l)           
Income tax expense impact of adjustments(m)  (0.04)  (0.07) (0.14)  (0.13)
Adjusted diluted earnings per share $0.13  $0.11 $0.30  $0.34 
        
Basic weighted average common shares outstanding  160,642,052   159,165,206  160,225,375   158,769,638 
Effect of potentially dilutive shares outstanding (n)  323,745   742,488  723,301   1,078,382 
Adjusted diluted weighted average common shares outstanding  160,965,797   159,907,694  160,948,676   159,848,020 
        

The following tables reconcile revenues to the revenues adjusted for constant currency:

               
  THREE MONTHS ENDED
SEPTEMBER 30,
 Change
  2024 2024 2023 $ % $ %
  Actual CC Actual Actual Actual CC Impact Adjust for CC
  (GAAP) (non-GAAP) (GAAP) (GAAP) (GAAP) (non-GAAP) (non-GAAP)
  (in thousands except percentage)
Revenue              
Software $35,912 $35,632 $31,331 $4,581 15% $(280) 14%
Services  58,908  58,654  54,245  4,663 9%  (254) 8%
Total Revenue $94,820 $94,286 $85,576 $9,244 11% $(534) 10%


  NINE MONTHS ENDED
SEPTEMBER 30,
 Change
   2024  2024  2023 $ % $ %
  Actual CC Actual Actual Actual CC Impact Adjust for CC
  (GAAP) (non-GAAP) (GAAP) (GAAP) (GAAP) (non-GAAP) (non-GAAP)
  (in thousands except percentage)
Revenue              
Software $113,426 $112,914 $98,058 $15,368 16% $(512) 15%
Services  171,361  170,711  168,269  3,092 2%  (650) 1%
Total Revenue $284,787 $283,625 $266,327 $18,460 7% $(1,162) 6%


(a.)Represents amounts as determined under GAAP.
(b.)Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.
(c.)Represents amortization costs associated with acquired intangible assets in connection with business acquisitions.
(d.)Represents expense associated with remeasuring fair value of contingent consideration of business acquisition.
(e.)Represents expense associated with goodwill impairment charge.
(f.)Represents costs associated with mergers and acquisitions and any retention bonuses pursuant to the acquisitions.
(g.)Represents integration costs related to post - acquisition integration activities.
(h.)Represents costs associated with our public offerings that are not capitalized, as well as debt issuance costs that are not deferred or treated as a contra-liability directly deducted from the carrying value of the associated debt liability.
(i.)Represents charges for severance provided to former executives.
(j.)Represents expense related to reorganization, including legal entity reorganization and lease abandonment cost associated with the evaluation of our office space footprint.
(k.)Represents the gain/loss related to disposal of fixed assets.
(l.)Represents recruiting and relocation expenses related to hiring senior executives.
(m.)Represents the income tax effect of the non-GAAP adjustments calculated using the applicable statutory rate by jurisdiction.
(n.)Represents potentially dilutive shares that were included from our GAAP diluted weighted average common shares outstanding.



FAQ

What was Certara's (CERT) revenue in Q3 2024?

Certara reported revenue of $94.8 million in Q3 2024, representing an 11% increase from $85.6 million in Q3 2023.

How much did Certara's (CERT) software revenue grow in Q3 2024?

Certara's software revenue grew 15% year-over-year to $35.9 million in Q3 2024, compared to $31.3 million in Q3 2023.

What is Certara's (CERT) updated revenue guidance for full-year 2024?

Certara updated its full-year 2024 revenue guidance to be in the range of $380 million to $385 million.

What was Certara's (CERT) net loss in Q3 2024?

Certara reported a net loss of $1.4 million in Q3 2024, compared to a net loss of $49.0 million in Q3 2023.

Certara, Inc.

NASDAQ:CERT

CERT Rankings

CERT Latest News

CERT Stock Data

1.57B
120.30M
2.6%
95.99%
3.33%
Health Information Services
Services-prepackaged Software
Link
United States of America
RADNOR